Compare OI & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OI | SRPT |
|---|---|---|
| Founded | 1903 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 1994 | 2000 |
| Metric | OI | SRPT |
|---|---|---|
| Price | $10.41 | $17.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 28 |
| Target Price | $17.57 | ★ $25.76 |
| AVG Volume (30 Days) | ★ 2.2M | 2.0M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,426,000,000.00 | $2,198,237,000.00 |
| Revenue This Year | $3.07 | N/A |
| Revenue Next Year | $1.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $9.23 | $10.42 |
| 52 Week High | $16.91 | $80.26 |
| Indicator | OI | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 24.09 | 45.46 |
| Support Level | N/A | $17.05 |
| Resistance Level | $13.46 | $19.55 |
| Average True Range (ATR) | 0.53 | 0.83 |
| MACD | -0.15 | 0.13 |
| Stochastic Oscillator | 1.03 | 63.11 |
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.